Preclinical trial of ALA iNKT therapy and IMU onCARlytics
Filed with ASX · · 4 pages · English
Arovella Therapeutics Limited on 6ix
In the deck
Earlier from Arovella Therapeutics
- Preliminary Final Report
- Quarterly Appendix 4C and Activities Report
- Sumatriptan Update
- ZolpiMist Launch Australia
- Adopts WEF Framework For ESG Reporting
Later from Arovella Therapeutics
- Arovella to close its Perth OroMist R&D Facility
- Europe Patent granted for iNKT Cell Therapy Platform
- R&D Tax Incentive refund received
- Arovella completes $1.65M placement
- ALA-101 confers survival benefit in leukemia model
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics